Wednesday’s reorg was designed to position the company for growth in the face of the imminent patent cliff for megablockbuster Lyrica.
Directing its reps to call on GPs with little to no opioid experience, Purdue introduced aggressive promotional tactics into the prescription opioid marketing playbook.
Biogen’s recently soaring stock price can be attributed to investor optimism in one of the most stubborn areas of drug development.
The deals follow last year’s additions of Cambridge BioMarketing and MicroMass Communications.
It’s still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.
The WPP agency is hoping its reorganization results in more collaboration among health and wellness staffers.
Insys founder John Kapoor has maintained his innocence in the face of charges.
Whether jurors will award a pharma Grand Prix, and whether US pharma will show up, are two open questions in the run-up to Lions Health.
You’ve seen what the biggies can do. What about the smaller end of the spectrum? MM&M’s second buyer’s guide to pharma, healthcare, and life sciences consulting services focuses on the dos and don’ts of hiring boutique firms.